Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Date:4/21/2009

- Pharmacologic Data Presented at American Association for Cancer Research's 100th Annual Meeting 2009 -

SOUTH SAN FRANCISCO, Calif. and DENVER, April 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the presentation of final data from a Phase 1 clinical study of an oral formulation of picoplatin in patients with solid tumors. Results showed that the bioavailability of oral picoplatin is nearly 100 percent at doses of 50 mg and 100 mg, indicating sufficient bioavailability to support further clinical development.

Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent in clinical development to treat a variety of solid tumors. It was designed to overcome platinum resistance of the tumor, which remains a medical challenge for oncologists and patients, whose therapeutic options become limited. Poniard is currently evaluating an intravenous formulation of picoplatin in a pivotal Phase 3 trial in patients with small cell lung cancer (SCLC) and in Phase 2 trials in metastatic colorectal cancer (CRC) and metastatic castration-resistant prostate cancer (CRPC).

"The results of the Phase 1 trial demonstrating the oral bioavailability of picoplatin support the continued development of an oral formulation for multiple tumor indications," said Robert De Jager, M.D., chief medical officer of Poniard. "We believe that oral picoplatin may offer opportunities for studies in new indications and in combinations with other chemotherapeutics or with radiation therapy. The administration options for oral picoplatin may provide more convenience to cancer patients and could enable the potential of multiple combination therapies."

The picoplatin data were presented today in a poster ses
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
5. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
6. Poniard Pharmaceuticals Receives Going Concern Qualification
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
9. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 The Little Gym of ... Soles4Souls, a charitable organization based in Nashville, Tennessee that provides ... proper footwear. A pair of shoes can, seriously, change the ... on their feet. Confidence, comfort, and health are all improved ... of shoes to play, grown, and live. Aside from the ...
(Date:9/22/2014)... In a collaboration that will encompass a broad ... patient care and accelerate personalized genomic medicine, The ... Center (BIDMC) have established a new academic, research ... , A recently signed agreement calls for JAX ... comprehensive relationship in the areas of research and ...
(Date:9/22/2014)... 22, 2014 A team of doctors ... mesothelioma is better than ever thanks to ongoing improvements ... article on its website. Click here to read ... and the Massey Cancer Center analyzed the average survival ... type of mesothelioma that occurs in the abdominal lining. ...
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... course from Winter & Alvin has just been ... excitement throughout the personal development community. The media ... attention of HonestyFirstReviews.com's Tiffany Hendricks prompting an investigative ... topic of great interest for many entrepreneurs and ...
(Date:9/22/2014)... The professional review website, Best Cheap Hosting ... companies and announced that Certified Hosting ( http://www.best-cheap-hosting-usa.com/go/CertifiedHosting/ ... hosting suppliers for webmasters who want to buy ... hosting) at affordable rates. , The spokesman for ... our customers will find many other creative ways ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston and Stride Rite Partner to Support Soles4Souls 2Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 2Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 3Health News:Report Says New Treatments Have Dramatically Improved Outcomes for People with Peritoneal Mesothelioma, According to Surviving Mesothelioma 2Health News:"The Millionaire's Brain" - A Review Examining Winter & Alvin's Training Course Released 2
... James M. Farrell, a,doctor of chiropractic practicing in Golden, ... (CCA). He was nominated,and chosen by his fellow doctors ... since 1992, Dr. Farrell has been extremely active,with the ... chair, board member,and executive board member prior to his ...
... 2007 Today researchers report a newly identified ... prostate cancer in African American men. This study, ... with prostate cancer in high-risk populations, is published online ... Prostate cancer is the second leading cause of cancer ...
... scientists say , WEDNESDAY, Oct. 31 (HealthDay News) -- Scientists ... catus ), an advance they say will lead to health ... for human disease. , A four-year-old Abyssinian cat named Cinnamon, ... was the subject of the genome sequencing by scientists with ...
... WEDNESDAY, Oct. 31 (HealthDay News) -- Screening MRIs can uncover ... As a matter of fact, that might happen more than ... found that 7.2 percent of those who received MRIs had ... aneurysms, and 1.6 had benign brain tumors. , "Our study ...
... 31 The Medicare bidding,program for durable medical ... homecare infrastructure" unless Congress modifies,the program. This is ... a,congressional subcommittee today by the American Association for ... patients,standard of care, choice of provider, and access ...
... - Haemacure Corporation,(TSX:HAE), a specialty bio-therapeutics company, announces ... Rodman & Renshaw 9th Annual,Healthcare Conference, on November ... York,Palace Hotel in New York. Rodman & ... presentation and,post the associated slides via its website ...
Cached Medicine News:Health News:Golden Doctor of Chiropractic Elected President of the Colorado Chiropractic Association 2Health News:Scientists discover genetic variant associated with prostate cancer in African Americans 2Health News:Brain MRIs Find Hidden Neurological Problems 2Health News:Brain MRIs Find Hidden Neurological Problems 3Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 3Health News:Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec 2
(Date:9/22/2014)... Sept. 22, 2014  CorMedix Inc. (NYSE MKT: ... commercializing therapeutic products for the prevention and treatment ... to announce that TUV-SUD and The Medicinal Evaluation ... (MEB) has granted its request for a label ... was initially approved in July 2013 for use ...
(Date:9/22/2014)... 2014 Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, announced ... appointed President and Chief Executive Officer, effective immediately.  Mr. Grossman ... down from his executive and Board roles but will ... first quarter of 2016.  Mr. Grossman ...
(Date:9/22/2014)... 2014 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced that its Board of Directors (the "Board") ... from Endo International plc ("Endo") and, after consulting ... unanimously determined it is not a superior proposal ... with QLT Inc. ("QLT") and has unanimously reaffirmed ...
Breaking Medicine Technology:Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
... 11, 2012  SuccessEHS announces that its newest release will ... when compared to previous releases.  The company has optimized ... (EHR) and Practice Management software solution ... upcoming release will focus on user efficiency and physician ...
... Jan. 11, 2012  nContact, Inc., the leading innovator ... recently launched corporate website, www.ncontactinc.com , has ... in Class Medical Site, presented by the nonprofit ... Studio 1440, has been recognized for excellence in ...
Cached Medicine Technology:Newest SuccessEHS Release to Increase Physician Software Usability 2Newest SuccessEHS Release to Increase Physician Software Usability 3nContact's Corporate Website Recognized as Best in Class Medical Site by Interactive Media Council - www.ncontactinc.com 2
... The ANA and ENA assays ... patients negative for antinuclear antibodies, which ... diseases such as Systemic lupus erythematosus ... disease, progressive systemic sclerosis, scleroderma, polymyositis, ...
... The ANA and ENA assays can ... negative for antinuclear antibodies, which are ... such as Systemic lupus erythematosus (Lupus), ... progressive systemic sclerosis, scleroderma, polymyositis, dermatomyositis, ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
... VerifyNow Clopidogrel Assay measures changes in ... taking Clopidogrel (Plavix). It uses a ... which clopidogrel inhibits. The assay has ... however, the assay is available for ...
Medicine Products: